ENDRA Life Sciences

ENDRA Life Sciences, Inc. develops medical imaging technology. It operates Thermo-Acoustic Enhanced UltraSound platform to enable clinicians to visualize human tissue composition, function and temperature. The company was founded on July 18, 2007 and is headquartered in Ann Arbor, MI.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ENDRA Life Sciences reports Q1 loss, eyes market expansion

ENDRA Life Sciences is navigating challenges in a competitive market while leveraging its strengths in innovation and strategic partnerships. The company's performance in Q1 2024 reflects progress in clinical research and regulatory alignment for its TAEUS system.

ENDRA Life Sciences charts strategic course for growth and innovation

ENDRA Life Sciences is making strategic changes to drive future growth and innovation. With a focus on regulatory alignment, clinical trials, and business strategy refinement, the company aims to enhance its market position. Despite financial challenges, ENDRA remains optimistic about its future performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today announced that the company will report financial results for the three months and year ended December 31, 2022 on Tuesday, March 14, 2023 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m.

ENDRA Life Sciences to Report Fourth Quarter and Full Year 2022 Financial Results on March 14, 2023

After losing some value lately, a hammer chart pattern has been formed for ENDRA Life Sciences Inc. (NDRA), indicating that the stock has found support. This, combined with an upward trend in earnings estimate revisions, could lead to a trend reversal for the stock in the near term.

Here's Why ENDRA Life Sciences Inc. (NDRA) Could be Great Choice for a Bottom Fisher

ANN ARBOR, Mich.--( BUSINESS WIRE )-- ENDRA Life Sciences Inc. (NASDAQ: NDRA) (the “Company”), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announced today that it will be effecting a reverse stock split of its outstanding shares of common stock at a ratio of 1-for-20. The reverse stock split will reduce the number of shares of the Company's common stock outstanding from 63,174,455 shares to approximately 3,158,723 shares, subject to adjustment for the rounding up of fractional shares. The Company is confirming with the Nasdaq Stock Market the effective date of the reverse stock split, when ENDRA's common stock will begin trading on a split-adjusted basis under the existing trading symbol “NDRA” and a new CUSIP number.

ENDRA Life Sciences Announces 1-for-20 Reverse Stock Split

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q3 2022 Earnings Conference Call November 14, 2022 4:30 PM ET Company Participants Yvonne Briggs - Investor Relations Francois Michelon - Chairman & Chief Executive Officer Michael Thornton - Chief Technology Officer Renaud Maloberti - Chief Commercial Officer Irina Pestrikova - Senior Director of Finance Conference Call Participants Edward Woo - Ascendiant Capital Operator Good day, and welcome to the ENDRA Life Sciences Third Quarter 2022 Financial Results Conference Call. All participants will be in a listen-only mode.

ENDRA Life Sciences Inc. (NDRA) Q3 2022 Earnings Call Transcript

ANN ARBOR, Mich.--( BUSINESS WIRE )--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and nine months ended September 30, 2022, and provided a business update. Highlights of the third quarter of 2022 and recent weeks include:

ENDRA Life Sciences Reports Third Quarter 2022 Financial Results and Provides Business Update

ENDRA Life Sciences to Report Third Quarter 2022 Financial Results on November 14, 2022

ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of Two U.S. Patents

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will present a company overview at the H.C. Wainwright 6th Annual NASH Investor Conference being held October 17, 2022 in a virtual format, and will also be holding one-on-one virtual meetings. To request a meeting, please contact H.C. Wainwright or Yvonne Briggs of LHA at ybriggs@lhai.com. About ENDRA Life Scie

ENDRA Life Sciences to Participate in the H.C. Wainwright 6th Annual NASH Investor Conference

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces an update to its plan to submit a De Novo request for the TAEUS system to the U.S. Food and Drug Administration (FDA). “I'm pleased to announce that preparation of the De Novo documentation by the end of the third quarter is substantially complete,” said ENDRA's Chairman and Chief Executive Officer Francois Michelon. “Our remai

ENDRA Life Sciences Plans to Submit De Novo Request to U.S. FDA for its TAEUS® System in Coming Weeks

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference being held September 12-14, 2022 in a virtual format and in-person in New York City and will be holding one-on-one meetings. A webcast of the presentation will be available on-demand beginning September 12, 2022 at 7:

ENDRA Life Sciences to Participate in Upcoming Investor and Industry Conferences

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the European Patent Office has issued European Patent No. 3730041 (the ‘041 patent) to ENDRA titled “System for Estimating Fractional Fat Content of an Object.” The ‘041 patent protects ENDRA's TAEUS system for the calculation of fat concentration in the human body with multiple thermoacoustic measurements. The ‘041 patent

ENDRA Life Sciences Announces Issuance of 8th European Patent for its TAEUS® System

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q2 2022 Earnings Conference Call August 15, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Edward Woo - Ascendiant Capital Vernon Bernardino - H.C. Wainwright Operator Good day everyone, and welcome to the ENDRA Life Sciences' Second Quarter 2022 Financial Results Conference Call.

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q2 2022 Results - Earnings Call Transcript

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three and six months ended June 30, 2022, and provided a business update. Highlights of the second quarter of 2022 and recent weeks include: Well capitalized through expected key milestones. With a cash position of approximately $11 million as of June 30, 2022, management believes ENDRA is capitalized to fund operations t

ENDRA Life Sciences Reports Second Quarter 2022 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (ENDRA) (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that the company will report financial results for the second quarter of 2022 on Monday, August 15, 2022 after the close of trading on the U.S. financial markets. Management will host a conference call and webcast beginning at 4:30 p.m. Eastern time to discuss the results, provide an update on recent corporate developments and answer questions. Parti

ENDRA Life Sciences to Report Second Quarter 2022 Financial Results on August 15, 2022

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of imaging technologies and Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent & Trademark Office has issued three new patents to ENDRA including U.S. Patent No. 11379343 (the ‘343 patent), U.S. Patent No. 11392479 (the ‘479 patent) and U.S. Patent No. 11405470 (the ‘470 patent). All three patents are titled “Methods and Systems for Exchange of Equipment Performance Data.

ENDRA Life Sciences Awarded Three Additional U.S. Patents for Cloud-enabled Connectivity of Medical Devices

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference being held August 15-16, 2022. Management will host one-on-one virtual meetings with investors. To request a meeting, please contact Needham or Yvonne Briggs of LHA at ybriggs@lhai.com. About ENDRA Life Sciences Inc. ENDRA Life Sciences is the pi

ENDRA Life Sciences to Participate in the 7th Annual Needham Virtual Med Tech & Diagnostics 1x1 Conference

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the Chinese National Intellectual Property Administration has issued two new patents to ENDRA, Chinese Patent No. ZL 2020 8 00151255 (the ‘255 patent) titled “Systems and Methods for Thermoacoustic Transducer Optimization” and Chinese Patent No. ZL 2020 8 00151433 (the ‘433 patent) titled “Method and System for Reconstructing a Thermoacoustic Imag

ENDRA Life Sciences Awarded Two Additional Chinese Patents for its TAEUS® System

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued a new ENDRA patent, U.S. Patent No. 11369272 (the ‘272 patent) titled “Broadband Applicator for Thermoacoustic Signal Generation.” The ‘272 patent protects TAEUS' radiofrequency (RF) applicator for optimizing the delivery of RF energy to tissue. Notably, the RF applicator utilizes a broad ba

ENDRA Life Sciences Enhances TAEUS® System Intellectual Property Portfolio with Issuance of 28th U.S. Patent

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, today announced that management will be participating in the JMP Securities Life Sciences Conference being held June 15-16, 2022 in New York City. Management will present a company overview on Wednesday, June 15th at 2:30 p.m. Eastern time and will host one-on-one meetings with investors. To request a meeting, please contact JMP Securities or Yvonne Briggs of LHA at ybriggs

ENDRA Life Sciences to Participate in the JMP Securities Life Sciences Conference

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent & Trademark Office has issued a new patent to ENDRA, U.S. Patent No. 11337676 (the ‘676 patent) titled “Acoustically Compatible Radio-frequency Applicator Method and System.” The ‘676 patent protects ENDRA's method and system for optimizing the delivery of radiofrequency (RF) energy to tissue using TAEUS, and serves as

ENDRA Life Sciences Bolsters TAEUS® System Intellectual Property with Issuance of 27th U.S. Patent

Ardelyx

Vinco Ventures

Why investors are buying these penny stocks right now The post Which Penny Stocks Are Investors Buying Right Now? 3 to Watch  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Which Penny Stocks Are Investors Buying Right Now? 3 to Watch

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of enhanced ultrasound technologies, announces that management will present a company overview at the H.C. Wainwright Global Investment Conference being held May 23-26, 2022 in Miami Beach and will be holding virtual one-on-one meetings. A webcast of the presentation will be available on-demand beginning May 24, 2022 at 7:00 a.m. Eastern time on the Investors section of ENDRA's website. About ENDRA Life Scienc

ENDRA Life Sciences to Present at the H.C. Wainwright Global Investment Conference

ENDRA Life Sciences Inc. (NASDAQ:NDRA ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants Yvonne Briggs - IR Francois Michelon - Chairman and CEO Mike Thornton - Chief Technology Officer Renaud Maloberti - CCO Irina Pestrikova - Senior Director, Finance Conference Call Participants Vernon Bernardino - H.C. Wainwright Edward Woo - Ascendiant Capital Operator Good afternoon everyone, and welcome to the ENDRA Life Sciences' First Quarter 2022 Financial Results Conference Call.

ENDRA Life Sciences Inc. (NDRA) CEO Francois Michelon on Q1 2022 Results - Earnings Call Transcript

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NAFLD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), today reported financial results for the three months ended March 31, 2022, and provided a business update. Highlights of the first quarter of 2022 and recent weeks include: Raised $8.7 million in gross proceeds, extending cash runway. The company raised a total of $8.7 million in gross proceeds year-to-date from the sale of common stock through its at-the-marke

ENDRA Life Sciences Reports First Quarter 2022 Financial Results and Provides Business Update

ANN ARBOR, Mich.--(BUSINESS WIRE)---- $NDRA #NALFD--ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces the issuance of four new patents, two in the U.S. and two in China. ENDRA's intellectual property portfolio now includes 90 assets, including 46 issued patents worldwide providing protection for the TAEUS system with its novel hybrid ultrasound and thermoacoustic imaging technology. One of the newly issued U.S. patents, which protects the ability to tr

News for ENDRA Life Sciences Stock (NDRA)